Premium
A meta‐analysis of XPC Lys939Gln polymorphism and melanoma susceptibility
Author(s) -
Jiang W.,
Zhang H.,
Chen Q.W.,
Xie S.
Publication year - 2016
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/jdv.13477
Subject(s) - meta analysis , medicine , melanoma , allele , genotype , polymorphism (computer science) , oncology , gastroenterology , bioinformatics , genetics , gene , cancer research , biology
Background It has been reported that polymorphisms of XPC Lys939Gln may affect the risk of melanom. However, the results have been inconsistent.We performed a comprehensive meta‐analysis to determine the association between XPC Lys939Gln polymorphism and melanoma susceptibility. Methods Based on comprehensive searches of the MEDLINE , EMBASE and ISI Web of knowledge, China National Knowledge Infrastructure ( CNKI ) and Wanfang Database, we identified eligible studies about the association between XPC Lys939Gln polymorphism and melanoma risk. Results A total of 4631 cases and 5111 controls in studies were included in this meta‐analysis. All studies were conducted in Caucasian populations. Allele model (Gln vs. Lys: P = 0.22; OR = 1.07, 95% CI = 0.96–1.18), and homozygous model (Gln/Gln vs. Lys/Lys: P = 0.66; OR = 1.03, 95% CI = 0.91–1.17) did not show increased risk of developing melanoma. Similarly, dominant model Gln/Gln and Gln/Lys vs. Lys/Lys: P = 0.07; OR = 1.17, 95% CI = 0.99–1.40) and recessive model (Gln/Gln vs. Gln/Lys and Lys/Lys: P = 0.67; OR = 1.03, 95% CI = 0.90–1.19) failed to show increased risk of developing melanoma. Conclusion Our pooled data suggest that there was no evidence for a major role of XPC Lys939Gln polymorphism in the pathogenesis of melanoma.